Sun Life Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sun Life Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-500	Closed	-$47K	–	625
2018 Q2	$47K	Buy	500 +459	+1,120%	+$40.2K	0.01%	439
2018 Q1	$500	Sell	41 -459	-92%	-$39.4K	﹤0.01%	433
2017 Q4	$45K	Hold	500	–	–	﹤0.01%	287
2017 Q3	$47K	Hold	500	–	–	﹤0.01%	456
2017 Q2	$45K	Buy	500 +456	+1,036%	+$41.5K	﹤0.01%	457
2017 Q1	$500	Buy	+44	New	+$3.91K	﹤0.01%	175

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sun Life Financial's BMRN Position: Q3 2018 in Review

Sun Life Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 500 shares — an estimated $47K sold.

Sun Life Financial first reported a position in BMRN in Q1 2017 and held it in 6 quarters. The position peaked at $47K in Q2 2018. 459 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

Sun Life Financial reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Sun Life Financial sold 500 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $47K.
Sun Life Financial first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Sun Life Financial's BioMarin Pharmaceuticals position peaked at $47K in Q2 2018.
459 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Sun Life Financial's 13F filing for Q3 2018, filed 13 Nov 2018.